Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02849990 · ClinicalTrials.gov registry record · Phase 2
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT02849990 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 22 participants.
The verdict
NCT02849990, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
This phase II trial studies how well apalutamide, abiraterone acetate, prednisone, degarelix, and indomethacin work in treating patients with prostate cancer that has spread from where it started to nearby tissue or lymph nodes before surgery. Androgen can cause the growth of tumor cells. Hormone therapy using apalutamide, abiraterone acetate, prednisone, degarelix, and indomethacin may fight prostate cancer by lowering the amount of androgen the body makes and/or blocking the use of androgen by the tumor cells.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Apalutamide
- DRUG Indomethacin
- DRUG Abiraterone Acetate
- DRUG Degarelix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2017-03-09 |
| Est. Completion | 2020-12-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02849990
The ClinicalTrials.gov registry entry for NCT02849990 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02849990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02849990 about?
NCT02849990 is a clinical study titled "A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy". This phase II trial studies how well apalutamide, abiraterone acetate, prednisone, degarelix, and indomethacin work in treating patients with prostate cancer that has spread from where it started to nearby tissue or lymph nodes before surgery. Androgen can cause the growth of tumor cells. Hormone th...
What is the current status of trial NCT02849990?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2017-03-09. Estimated completion is 2020-12-10.
What interventions are being tested in trial NCT02849990?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Apalutamide (DRUG), Indomethacin (DRUG), Abiraterone Acetate (DRUG), Degarelix (DRUG).
Who is sponsoring clinical trial NCT02849990?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.